TW279866B - - Google Patents

Info

Publication number
TW279866B
TW279866B TW083104441A TW83104441A TW279866B TW 279866 B TW279866 B TW 279866B TW 083104441 A TW083104441 A TW 083104441A TW 83104441 A TW83104441 A TW 83104441A TW 279866 B TW279866 B TW 279866B
Authority
TW
Taiwan
Application number
TW083104441A
Other languages
Chinese (zh)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of TW279866B publication Critical patent/TW279866B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW083104441A 1993-05-21 1994-05-17 TW279866B (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939310635A GB9310635D0 (en) 1993-05-21 1993-05-21 Chemical compounds

Publications (1)

Publication Number Publication Date
TW279866B true TW279866B (cs) 1996-07-01

Family

ID=10736007

Family Applications (1)

Application Number Title Priority Date Filing Date
TW083104441A TW279866B (cs) 1993-05-21 1994-05-17

Country Status (19)

Country Link
EP (1) EP0699196A1 (cs)
JP (1) JPH08510455A (cs)
CN (1) CN1126473A (cs)
AU (1) AU6928794A (cs)
BG (1) BG100154A (cs)
CA (1) CA2162921A1 (cs)
CZ (1) CZ305195A3 (cs)
FI (1) FI955587A0 (cs)
GB (1) GB9310635D0 (cs)
HU (1) HUT73790A (cs)
IL (1) IL109703A0 (cs)
NO (1) NO954681D0 (cs)
OA (1) OA10195A (cs)
PE (1) PE31195A1 (cs)
PL (1) PL311702A1 (cs)
SK (1) SK142495A3 (cs)
TW (1) TW279866B (cs)
WO (1) WO1994027989A1 (cs)
ZA (1) ZA943494B (cs)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009157A1 (en) * 1993-09-30 1995-04-06 Yamanouchi Pharmaceutical Co., Ltd. Azole derivative and pharmaceutical composition thereof
WO1996014090A1 (en) * 1994-11-07 1996-05-17 Janssen Pharmaceutica N.V. Compositions comprising carbazoles and cyclodextrins
EP0820989A4 (en) * 1995-03-01 1998-05-06 Yamanouchi Pharma Co Ltd IMIDAZOLE DERIVATIVES AND MEDICINAL COMPOSITION BASED ON SAID DERIVATIVES
DE69810760T2 (de) * 1997-02-21 2003-11-20 Takeda Chemical Industries, Ltd. Verbindungen mit kondensierten ringen, verfahren zu ihrer herstellung und ihre anwendung
DE60119963T2 (de) 2000-11-17 2006-10-05 Takeda Pharmaceutical Co. Ltd. Imidazol derivate, ihre herstellung und ihre verwendung
ATE502030T1 (de) 2000-11-20 2011-04-15 Takeda Pharmaceutical Imidazolderivate, verfahren zu deren herstellung und deren verwendung
EP1348706B1 (en) 2000-12-08 2009-08-19 Takeda Pharmaceutical Company Limited Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
WO2007002181A2 (en) * 2005-06-24 2007-01-04 Eli Lilly And Company Tetrahydrocarbazole derivatives useful as androgen receptor modulators (sarm)
GB0525323D0 (en) * 2005-12-13 2006-01-18 Sterix Ltd Compound
US8093279B2 (en) 2005-12-13 2012-01-10 Gillian Reed, legal representative Compound
CN100586932C (zh) * 2007-01-26 2010-02-03 中国医学科学院医药生物技术研究所 抗肿瘤化合物及其制备方法
EA021011B1 (ru) 2009-06-26 2015-03-31 Новартис Аг 1,3-ДИЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ИМИДАЗОЛИДИН-2-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ Cyp 17
JP5964756B2 (ja) 2010-02-04 2016-08-03 ラジウス ヘルス,インコーポレイテッド 選択的アンドロゲン受容体モジュレーター
PT2568806T (pt) 2010-05-12 2016-08-05 Radius Health Inc Regimes terapêuticos
WO2012018948A2 (en) 2010-08-04 2012-02-09 Pellficure Pharmaceuticals, Inc. Novel treatment of prostate carcinoma
JP2013537210A (ja) 2010-09-16 2013-09-30 ノバルティス アーゲー 17α−ヒドロキシラーゼ/C17,20−リアーゼ阻害剤
WO2012047617A1 (en) 2010-09-28 2012-04-12 Radius Health, Inc. Selective androgen receptor modulators
CN103649073B (zh) 2011-04-28 2016-04-13 诺瓦提斯公司 17α-羟化酶/C17,20-裂合酶抑制剂
US9492460B2 (en) * 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
US20160022606A1 (en) 2013-03-14 2016-01-28 Pellficure Pharmaceuticals Inc. Novel therapy for prostate carcinoma
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
LT3122426T (lt) 2014-03-28 2023-03-10 Duke University Krūties vėžio gydymas, naudojant selektyvius estrogenų receptorių moduliatorius
EP3191087A1 (en) 2014-09-12 2017-07-19 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
PL3474841T3 (pl) 2016-06-22 2022-07-11 Ellipses Pharma Ltd Sposoby leczenia nowotworu złośliwego piersi ar+
AU2017350690A1 (en) 2016-10-24 2019-06-13 Pellficure Pharmaceuticals Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione
KR102557321B1 (ko) 2017-01-05 2023-07-18 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS229934B2 (en) * 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
GB8518743D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds

Also Published As

Publication number Publication date
OA10195A (en) 1996-12-18
EP0699196A1 (en) 1996-03-06
FI955587A7 (fi) 1995-11-20
SK142495A3 (en) 1996-06-05
FI955587A0 (fi) 1995-11-20
ZA943494B (en) 1995-01-23
WO1994027989A1 (en) 1994-12-08
CN1126473A (zh) 1996-07-10
NO954681L (no) 1995-11-20
CZ305195A3 (en) 1996-06-12
GB9310635D0 (en) 1993-07-07
BG100154A (en) 1996-07-31
HUT73790A (en) 1996-09-30
HU9503321D0 (en) 1996-01-29
NO954681D0 (no) 1995-11-20
PL311702A1 (en) 1996-03-04
JPH08510455A (ja) 1996-11-05
CA2162921A1 (en) 1994-12-08
AU6928794A (en) 1994-12-20
IL109703A0 (en) 1994-08-26
PE31195A1 (es) 1995-10-18

Similar Documents

Publication Publication Date Title
FR10C0052I2 (cs)
FR04C0020I1 (cs)
FR04C0010I1 (cs)
EP0690955A4 (cs)
TW279866B (cs)
FR2700330B1 (cs)
FR2701701B1 (cs)
FR2700841B1 (cs)
EP0707697A4 (cs)
EP0641839A3 (cs)
ECSDI930112S (cs)
ECSDI930098S (cs)
IN177795B (cs)
ECSDI930115S (cs)
ECSDI930123S (cs)
ECSDI930139S (cs)
ECSDI930163S (cs)
ECSDI930165S (cs)
ECSDI930167S (cs)
ECSMU930016U (cs)
ECSMU930028U (cs)
CU22254A3 (cs)
DK113593D0 (cs)
DK121593D0 (cs)
DK122793D0 (cs)